Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amilomotide
- Development stage
- Phase 3
- Lead developer
- Novartis
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Amilomotide (CAD106)** is an investigational active immunotherapy vaccine developed for Alzheimer's disease, consisting of a virus-like particle (Qb) carrier coupled with a fragment of beta-amyloid protein. It induces antibodies against beta-amyloid to inhibit plaque formation in the brain. Developed initially by Cytos Biotechnology and later by Novartis, it was administered via intramuscular injections and showed serological responses in clinical trials but faced tolerability issues and trial terminations.
- Brand names
- Amilomotide
- Other names
- Alzheimer's disease virus-like particle-based vaccineAlzheimer's disease VLP-based vaccineBeta-amyloid protein immunotherapy
02
Targets
Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on amilomotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amilomotide.